Collaboration – University of Copenhagen

CeBIL > Collaboration

Collaboration

CeBIL is international and interdisciplinary. It collaborates with key national and international experts from academia, public bodies, patient organizations and industry. Some of the most renowned international academic capacities in biomedical innovation law are expected to be involved in CeBIL as either Core Partners or Collaborators. The expected CeBIL Core Partners are listed below. They are expected to lead and/or be actively involved in one or more of the 6 CeBIL studies. Through their role in the CeBIL Management Team, they are further expected to contribute to and influence the development and progress of the programme:

CORE PARTNERS
University of Copenhagen
Department of Food and Resource Economics (IFRO), UCPH

Associate Professor Marcel Bogers and Assistant Professor Karin Beukel from the Unit for Innovation, Entrepreneurship and Management at IFRO will contribute expertise in the economics and management of innovation with a specific focus on analysis and methodology and special skills in IP management, business models and open innovation.
University of Cambridge Centre for Law, Medicine and Life Sciences, University of Cambridge

Director, Dr. Kathleen Liddell will contribute expertise on intellectual property rights, patents and translational medicine. In addition, Professor Lionel Bentley (IP, trademarks, patents), Dr. Jeffrey Skopek (thics, big data, personalised medicine), Dr. Stuart Hogarth (empirical studies, biomedical innovation, regulatory governance) and Dr. Mateo Aboy (biomedical engineering, patents, IP landscaping big data) will participate and contribute to CeBIL.
Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, Harvard Law School Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, Harvard Law School

Faculty Director, Professor I.G. Cohen. Cohen will contribute expertise on the intersection of bioethics/medical ethics and the law with a specific focus on big data, policy and translational medicine.
PORTAL - Program on Regulation, Therapeutics and Law, Harvard Medical School and Brigham & Women’s Hospital PORTAL - Program on Regulation, Therapeutics and Law, Harvard Medical School and Brigham & Women’s Hospital

Head of PORTAL, Associate Professor Aaron Kesselheim will contribute both medical and legal expertise in relation to a.o. antibiotics, pharmaceutical development, and patents. In addition, the Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and Women’s Hospital/Harvard Medical School is also expected to become a core partner.
University of Michigan Law School University of Michigan Law School

Dr. Nicholson Price will contribute with special expertise in drug manufacturing, patent law, regulatory governance, health law, personalized medicine, big data.